Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 4/20 | 0.50 |
| ▸ | MIF | P14174 | 4/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | MAOB | P27338 | 2/20 | 0.42 |
| ▸ | ERN1 | O75460 | 1/20 | 0.41 |
| ▸ | MCHR1 | Q99705 | 2/20 | 0.41 |
| ▸ | NCF1 | P14598 | 3/20 | 0.41 |
| ▸ | CNR2 | P34972 | 1/20 | 0.40 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.40 |
| ▸ | SOAT1 | P35610 | 1/20 | 0.40 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL484300 | 0.91 | MAPT (0.53) | MAPTMIFMAOBNCF1CNR2 | |
| SCHEMBL12402789 | 0.89 | MAPT (0.50) | MAPTMIFMAOBNCF1KCNH2 | |
| SCHEMBL483920 | 0.88 | MAPT (0.56) | MAPTMIFNCF1 | |
| SCHEMBL12403478 | 0.79 | MIF (0.52) | MAPTMIFNCF1 | |
| SCHEMBL483802 | 0.78 | MAPT (0.55) | MAPTMIFNCF1 | |
| SCHEMBL12402791 | 0.77 | MAPT (0.57) | MAPTMIFMAOBNCF1 | |
| SCHEMBL13127319 | 0.76 | MAPT (0.53) | MAPTMIFNCF1 | |
| SCHEMBL21974576 | 0.75 | MAPT (0.65) | MAPTMIFNCF1 | |
| SCHEMBL12403523 | 0.75 | MAPT (0.65) | MAPTMIFNCF1 | |
| SCHEMBL12323618 | 0.73 | CA12 (0.46) | MAPTMIFHPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2411057-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-2411057-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2020-05-06 | — | — | EP | disclosed |
| EP-2550255-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2016-04-27 | — | — | EP | disclosed |
| EP-2550255-B1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | LILLY CO ELI (US) | 2016-04-27 | — | — | EP | disclosed |
| US-20130302248-A1 | Imaging Agents for Detecting Neurological Disorders | LILLY CO ELI (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130302248-A1 | Imaging Agents for Detecting Neurological Disorders | LILLY CO ELI (US) | 2013-11-14 | — | — | US | disclosed |
| US-20130302248-A1 | Imaging Agents for Detecting Neurological Disorders | LILLY CO ELI (US) | 2013-11-14 | — | — | US | disclosed |
| US-8491869-B2 | Imaging agents for detecting neurological disorders | ELI LILLY AND COMPANY (US) | 2013-07-23 | — | — | US | disclosed |
| US-8491869-B2 | Imaging agents for detecting neurological disorders | ELI LILLY AND COMPANY (US) | 2013-07-23 | — | — | US | disclosed |
| EP-2411057-A2 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | Siemens Medical Solutions USA, Inc. (US) | 2012-02-01 | — | — | EP | disclosed |
| WO-2011119565-A1 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-09-29 | — | — | WO | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2011-07-28 | — | — | US | disclosed |
| WO-2010111303-A2 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| WO-2010111303-A2 | IMAGING AGENTS FOR DETECTING NEUROLOGICAL DISORDERS | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-09-30 | — | — | WO | disclosed |
| US-20100239496-A1 | Imaging agents for detecting neurological disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100239496-A1 | Imaging agents for detecting neurological disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-09-23 | — | — | US | disclosed |
| US-20100239496-A1 | Imaging agents for detecting neurological disorders | SIEMENS MEDICAL SOLUTIONS USA, INC. (US) | 2010-09-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130302248-A1 | Imaging Agents for Detecting Neurological Disorders | MAPT, APP, PSEN1 | MAPT 1/4885MIF 2518/4885HPGD 3799/4885 |
| US-20110182812-A1 | Imaging Agents for Detecting Neurological Disorders | MAPT, APP, PSEN1 | MAPT 1/4885MIF 2151/4885HPGD 3802/4885 |
| US-20100239496-A1 | Imaging agents for detecting neurological disorders | MAPT, APP, PSEN1 | MAPT 1/4885MIF 2518/4885HPGD 3799/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.